Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 1/20 | 0.68 |
| ▸ | NAAA | Q02083 | 15/20 | 0.67 |
| ▸ | ASAH1 | Q13510 | 3/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17557250 | 1.00 | CCR2 (0.68) | CCR2NAAAASAH1CYP1A2CYP2D6 | |
| SCHEMBL16071259 | 1.00 | CCR2 (0.68) | CCR2NAAAASAH1CYP1A2CYP2D6 | |
| SCHEMBL3316920 | 0.81 | CCR2 (1.00) | CCR2NAAA | |
| SCHEMBL17556906 | 0.81 | NAAA (1.00) | CCR2NAAAASAH1 | |
| SCHEMBL28421652 | 0.81 | CCR2 (0.61) | CCR2NAAACYP1A2CYP2D6CYP2C9 | |
| SCHEMBL19646665 | 0.81 | NAAA (1.00) | CCR2NAAAASAH1 | |
| SCHEMBL17577510 | 0.72 | NAAA (0.62) | NAAAASAH1 | |
| SCHEMBL13761426 | 0.71 | CYP1A2 (0.64) | CCR2NAAACYP1A2CYP2D6CYP2C9 | |
| SCHEMBL16058307 | 0.70 | NAAA (1.00) | CCR2NAAA | |
| SCHEMBL16071308 | 0.70 | NAAA (1.00) | CCR2NAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9908848-B2 | Amide derivatives of lactam based N-acylethanolamine acid amidase (NAAA) inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-03-06 | — | — | US | disclosed |
| US-20160068483-A1 | AMIDE DERIVATIVES OF LACTAM BASED N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2016-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160068483-A1 | AMIDE DERIVATIVES OF LACTAM BASED N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) INHIBITORS | NAAA, FAAH, FAAH2 | CCR2 3813/4885NAAA 1/4885ASAH1 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.